Physician profile
Mohammad N Sabbagh
NPI 1497857148
$3,934.67
in general payments reported to CMS, 2019-2025
34 companies · $233 in 2025
The $233 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,200 · 2020: $660 · 2021: $536 · 2022: $608 · 2023: $459 · 2024: $239 · 2025: $233.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $930.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $930.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $583.05 | 2019-2023 | |
| Biogen, INC. | $532.09 | 2019-2024 | Tysabri |
| Emd Serono, INC. | $311.90 | 2019-2025 | Mavenclad |
| Janssen Pharmaceuticals, INC | $225.65 | 2019-2023 | Ponvory |
| Genzyme Corporation | $219.38 | 2019-2025 | |
| Abbvie INC. | $209.20 | 2021-2024 | Vraylar |
| Ucb, INC. | $204.54 | 2019-2023 | Fintepla, Briviact |
| Acorda Therapeutics, INC | $202.18 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $190.95 | 2019-2021 | |
| Incyte Corporation | $142.11 | 2022-2025 | Jakafi |
| Amgen INC. | $118.59 | 2019-2025 | Uplizna |
| Teva Pharmaceuticals USA, INC. | $105.01 | 2019-2020 | |
| Horizon Therapeutics Plc | $103.50 | 2021-2023 | Uplizna |
| Acadia Pharmaceuticals INC | $88.50 | 2019-2021 | |
| Nalu Medical, INC. | $85.10 | 2023 | Nalu Neurostimulation System |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $80.44 | 2019-2025 | |
| Lilly USA, LLC | $62.06 | 2019-2025 | Kisunla, Emgality |
| Celgene Corporation | $61.43 | 2022-2025 | Zeposia |
| Adamas Pharmaceuticals, INC. | $51.56 | 2019-2021 | |
| Allergan, INC. | $45.50 | 2019-2021 | |
| Eisai INC. | $37.25 | 2020-2022 | |
| Nevro Corp. | $32.05 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $28.86 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $24.92 | 2022 | |
| Kyowa Kirin, INC. | $24.87 | 2021 | |
| Grifols USA, LLC | $23.63 | 2021 | |
| Otter Pharmaceuticals, LLC | $23.47 | 2025 | Sympazan |
| Neurelis, INC. | $19.71 | 2021 | |
| Alnylam Pharmaceuticals INC. | $18.97 | 2022 | |
| Cordis US Corp. | $17.76 | 2025 | Precise Pro Rx |
| Genentech USA, INC. | $17.01 | 2019 | |
| Harmony Biosciences LLC | $15.40 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.58 | 2022 | |
| Tanabe Pharma America, INC. | $13.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Sabbagh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.